- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04902157
Relationship Between CT- Value With Prognosis in COVID-19 Patients
July 15, 2023 updated by: nooshin dalili, Shahid Beheshti University of Medical Sciences
evaluate the relationship between cycle threshold number with final prognosis in COVID-19 patients
Study Overview
Detailed Description
evaluate the relationship between cycle threshold number with final prognosis in COVID-19 patients
Study Type
Observational
Enrollment (Actual)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Nooshin Dalili
-
Tehran, Iran, Islamic Republic of, 1666664321
- SBMU
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
COVID-19 PCR Positive
Description
Inclusion Criteria:
- COVID-19 PCR positive
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
prognosis
Time Frame: 6 months
|
death or alive
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2021
Primary Completion (Actual)
January 1, 2022
Study Completion (Actual)
February 1, 2022
Study Registration Dates
First Submitted
May 25, 2021
First Submitted That Met QC Criteria
May 25, 2021
First Posted (Actual)
May 26, 2021
Study Record Updates
Last Update Posted (Actual)
July 18, 2023
Last Update Submitted That Met QC Criteria
July 15, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBMU.34.675
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
PfizerActive, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionUnited States
-
Shanghai Public Health Clinical CenterNot yet recruiting
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)Germany
-
PfizerRecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionBelgium
-
ModeX Therapeutics, An OPKO Health CompanyRecruitingCOVID -19 | COVID-19 (Prevention)United States
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID ConditionCanada
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
University of Missouri, Kansas CityNational Institute on Minority Health and Health Disparities (NIMHD)Active, not recruitingCOVID-19 Testing BehaviorsUnited States
Clinical Trials on Cycle threshold
-
Zhujiang HospitalSun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Guangzhou Institute... and other collaboratorsCompletedChronic Obstructive Pulmonary Disease (COPD)China
-
Zhujiang HospitalCompletedChronic Obstructive Pulmonary Disease (COPD)China
-
Zhenfeng HeGuangzhou Medical UniversityUnknownVentilation | Rehabilitation | CopdChina
-
Universidade Federal de PernambucoCompleted
-
NICHD Neonatal Research NetworkNational Heart, Lung, and Blood Institute (NHLBI)RecruitingInfant, Newborn, Diseases | Thrombosis | Thrombocytopenia | Infant, Extremely Low Birth Weight | Infant, Small for Gestational Age | Neonatal | Platelet TransfusionUnited States
-
IRCCS San RaffaeleCompleted
-
Ospedali Riuniti TriesteCompleted
-
University of ValenciaCompletedRotator Cuff TendinitisSpain
-
Shenzhen TargetRx, Inc.The First Affiliated Hospital of Bengbu Medical UniversityCompleted
-
University of AarhusCompleted